NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

645 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2017-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779

Epilepsy; Seizure Neuromuscular Diseases Brain Malformation +14 more

COMPLETED NA

North Carolina Newborn Exome Sequencing for Universal Screening

NCT02826694

Metabolism, Inborn Errors Hearing Loss Hereditary Disease

COMPLETED NA

Clinical Implementation of Carrier Status Using Next Generation Sequencing

NCT01902901

Genetic Disorders

COMPLETED NA

Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols

NCT01375543

Genetic Predisposition

COMPLETED

Investigating the Feasibility and Implementation of Whole Genome Sequencing in Patients With Suspected Genetic Disorder

NCT03829176

Hereditary Disease Genetic Predisposition to Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the University of North Carolina Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA (Clinical Laboratory Improvement Amendments)-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are described here.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Cardiovascular Disease Neurologic Dysfunction Congenital Abnormalities Hearing Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Option to request non-medically actionable incidental information (after receiving education about them)

Group Type EXPERIMENTAL

Experimental

Intervention Type BEHAVIORAL

Option to request non-medically actionable incidental information (after receiving education about them)

Control

No option to request non-medically actionable incidental information

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental

Option to request non-medically actionable incidental information (after receiving education about them)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- To receive whole exome sequencing in the study, adult or child patients must have a significant chance of having a genetic disorder, as determined by experts on the study team using criteria that depend on the genetic disorder in question. Representative criteria are listed below and will be considered together to determine whether patterns indicate a likely genetic etiology.

Cancer

* Age of diagnosis
* Presence of bilateral (or multiple) cancers
* Diagnosis of a rare type of cancer
* Details of the family history

Cardiovascular Conditions

* Certain clinical findings, such as prolonged QT interval on electrocardiogram.
* Presence of hypertrophic cardiomyopathy or aortic aneurysm
* Age of diagnosis
* Presence of family history

Pediatric neurodevelopmental disorders

* Specific brain structural brain abnormalities
* Presence of certain seizure types
* Dysmorphic features

Eligible Sex

ALL

Accepts Healthy Volunteers

No